Cardio Vascu-Grow for treatment of coronary heart disease - Article CABG
Clinical Trial: Cardio Vascu-Grow for treatment of coronary heart disease
This study is currently recruiting patients.
Treatment for no-options heart patients with coronary artery disease. Procedure involves the injection into the heart of a protein growth factor that stimulates the growth of new blood vessels around blocked coronary arteries.
|Condition||Treatment or Intervention||Phase|
|Coronary Disease |
Coronary Heart Disease
| Drug: Human Fibroblast Growth Factor 1 ||Phase I |
MedlinePlus related topics: Coronary Disease; Heart Diseases; Heart Diseases--Prevention; Vascular Diseases
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Expected Total Enrollment: 32
Study start: December 2002
Patients with chronic, stable angina with documented coronary artery disease are eligible for the study.
Ages Eligible for Study: 25 Years - 90 Years, Genders Eligible for Study: Both
3 month history of chronic, stable angina.
Mini-thoracotomy and anesthesia not contraindicated.
Not eligible for by-pass or PTCA procedures.
One/two/three vessel disease with documentation of greater than 70% narrowing of a major coronary artery, or diffuse coronary artery disease.
Heart ejection fraction >25%.
Normal retinal eye exam.
Subjects must be on conventional medication including one of the following: beta-blockers, calcium entry blockers, long-acting nitrates.
Female subjects must be post-menopausal or sterilized, or if of child-bearing age, not breast-feeding, on contraceptive drugs or devices, and have no intention of becoming pregnant during the course of the study.
Location and Contact Information
St. Joseph Medical Center, Towson, Maryland, 21204, United States; Recruiting
Mary Riggs, R.N. 301-208-9100 Maryr@C2R.net
John C Laschinger, M.D., Principal Investigator
Penn State Milton Hershey Medical Center, Hershey, Pennsylvania, 17033, United States; Recruiting
John Boehmer, M.D., Principal Investigator
web site of sponsor
Record last reviewed: December 2002
Last Updated: October 13, 2004
Record first received: March 14, 2002
ClinicalTrials.gov Identifier: NCT00032318
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Cache Date: April 9, 2005